Home/Pipeline/Cyto-MSC Acute Stroke

Cyto-MSC Acute Stroke

Acute Ischemic Stroke

Phase 2Active

Key Facts

Indication

Acute Ischemic Stroke

Phase

Phase 2

Status

Active

Company

About Cytopeutics

MSC‑based cell therapy platform with halal‑certified products for Asia‑Pacific clinical markets.

View full company profile

Therapeutic Areas

Cardiovascular Neurology Metabolic Ophthalmology Orthopedics Oncology Immunology

Other Acute Ischemic Stroke Drugs

Drug	Company	Phase	Status
Presendin™ (Exenatide)	Invex Therapeutics	Phase 2	Active
Supernova Stent Retriever	Gravity Medical Technology	Commercial	Active
Neutron Reperfusion Catheter	Gravity Medical Technology	Commercial	Active
AST-004	Astrocyte Pharmaceuticals	Phase 1/2	IND cleared March 2024
scp776	Silver Creek Pharmaceuticals	Phase 2	Active
VB-001	VST Bio	Pre-clinical	Active
Pulse NanoMED for AIS	Euphrates Vascular	Pre-clinical	Active
NeVa NET	Vesalio	Development/Commercial	Active
ApTOLL	aptaTargets	Phase 2	Transferred
ThermoSuit® for Acute Ischemic Stroke	Life Recovery Systems HD	Pivotal Trial (Planned)	Active
Pulsante for Ischemic Stroke	Realeve	Research/Clinical Study	Active
Glenzocimab (ACT017)	Acticor Biotech	Phase 2/3	Active